Clinical evaluation of weekly 1-hour infusion of paclitaxel in patients with hormone-refractory prostate cancer

被引：0
|
作者：
Hussain, M
机构：
[1] Wayne State Univ, Detroit, MI USA
[2] Karmanos Canc Inst, Detroit, MI USA
来源：
SEMINARS IN ONCOLOGY | 1999年 / 26卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：138 / 138
页数：1
相关论文
共 50 条
  • [31] CONTINUOUS INFUSION OF VINBLASTINE FOR ADVANCED HORMONE-REFRACTORY PROSTATE-CANCER
    DEXEUS, F
    LOGOTHETIS, CJ
    SAMUELS, ML
    HOSSAN, E
    VONESCHENBACH, AC
    CANCER TREATMENT REPORTS, 1985, 69 (7-8): : 885 - 886
  • [32] Paclitaxel via 1-hour infusion: Rationale and pharmacology
    Greco, FA
    Hainsworth, JD
    SEMINARS IN ONCOLOGY, 1996, 23 (06) : 19 - 20
  • [33] Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients
    Bertelli, G
    Heouaine, A
    Arena, G
    Botto, A
    Garrone, O
    Colantonio, I
    Occelli, M
    Fea, E
    Giubergia, S
    Merlano, M
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (01) : 46 - 51
  • [34] Phase II study of ketoconazole combined with weekly doxorubicin in patients with hormone-refractory prostate cancer
    Argirovic, D.
    Argirovic, A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (08) : 568 - 568
  • [35] Update in the management of patients with hormone-refractory prostate cancer
    Moore, CN
    George, DJ
    CURRENT OPINION IN UROLOGY, 2005, 15 (03) : 157 - 162
  • [36] Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)
    Kattan, Joseph G.
    Farhat, Fady S.
    Chahine, Georges Y.
    Nasr, Fady L.
    Moukadem, Walid T.
    Younes, Fariha C.
    Yazbeck, Nadine J.
    Ghosn, Marwan G.
    INVESTIGATIONAL NEW DRUGS, 2008, 26 (01) : 75 - 79
  • [37] Treatment of patients with hormone-refractory prostate cancer with mitoxantrone
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 95 - 95
  • [38] Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)
    Joseph G. Kattan
    Fady S. Farhat
    Georges Y. Chahine
    Fady L. Nasr
    Walid T. Moukadem
    Fariha C. Younes
    Nadine J. Yazbeck
    Marwan G. Ghosn
    Investigational New Drugs, 2008, 26 : 75 - 79
  • [39] Phase II trial of weekly 1-hour paclitaxel (PAC) for metastatic breast cancer
    Seuderi, C
    Crivellari, D
    Magri, MD
    Di Lauro, V
    Lombardi, D
    Paolello, C
    Spazzapan, S
    Veronesi, A
    ANNALS OF ONCOLOGY, 2000, 11 : 48 - 48
  • [40] Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma
    Falcone, A
    Antonuzzo, A
    Danesi, R
    Allegrini, G
    Monica, L
    Pfanner, E
    Masi, G
    Ricci, S
    Del Tacca, M
    Conte, P
    CANCER, 1999, 86 (03) : 470 - 476
12345